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Summary The effect of delayed uridine administration on the in vitro growth inhibitory effects of
5-fluorouracil (5FU) and on the in vivo antitumour activity and toxicity was studied. In vitro growth inhibi-
tion of the human intestinal cell lines WiDr and Intestine 407 by 3 /M 5FU could be reversed by 1.0mM
uridine; the effect was more pronounced with WiDr cells. At 0.1 mM uridine an intermediate effect was
observed. Inhibition of colony formation in both cell lines could also be reversed by delayed administration of
uridine at 0.1 and 1mM. Incorporation of 5FU into RNA of WiDr cells did not proceed after addition of
uridine, in contrast to Intestine 407 cells. In these cells only a partial inhibition was observed.
In vivo we studied the effect of uridine on two colon carcinoma tumour lines, the 5FU senstitive Colon 38
and the relatively resistant Colon 26. 5FU was administered i.p. in a weekly schedule. With Colon 26 delayed
administration of uridine (3500mgkg-1) at 2 and 20h after 5FU enabled us to increase the 5FU dose from
100 to 250-300mgkg-1. The combination of high-dose 5FU and uridine resulted both in a superior
antitumour effect and an increase in life span. In the 5FU sensitive Colon 38 we determined whether the
sensitivity to 5FU was affected by uridine. Mice were treated at the non-lethal dose of 100mgkg-1 which
inhibited tumour growth almost completely. Delayed administration of uridine did not significantly affect the
antitumour effect. In non-tumour bearing mice we studied the time course of the reversal of the
haematological toxicity of 5FU. The effective dose of 100mgkg- 1 induced a significant decrease in
leukocytes; in combination with delayed uridine the leukopenia was less severe and recovered more rapidly.
5FU also induced a decrease in haematocrit, which could be prevented by delayed administration of uridine.
In conclusion, in cell culture the reversal of 5FU cytotoxicity could be achieved at a low concentration of
0.1 mM uridine, the extent of the reversal might be related to the 5FU incorporation into RNA. In vivo the
relatively resistant tumour Colon 26 could be treated with a higher dose of 5FU in the presence of uridine.
The sensitivity to 5FU of the sensitive Colon 38 was not affected by delayed administration of uridine, while
the haematological toxicity of 5FU was less. So, delayed administration of uridine after 5FU resulted in an
improved therapeutic effect in both a relatively resistant and sensitive tumour.
5-Fluorouracil (5FU) is widely used for palliative treatment
of colorectal cancer (Chabner, 1982). However, total
response rates of monotherapy with 5FU do not exceed
20%. Depending on scheduling either gastrointestinal or
haematological toxicity is dose-limiting (Chabner, 1982). The
mechanism of action of 5FU is rather complicated. 5FU
conversion to nucleotides can follow different pathways
depending on the characteristics of the cell (Peters et al.,
1986). 5-Fluoro-2'deoxyuridine-5'monophosphate (FdUMP)
inhibits DNA synthesis by formation of a ternary complex
with thymidylate synthase and 5,10-methylene-tetrahydro-
folate. 5-Fluoro-uridine-5'-triphosphate (FUTP) may be
incorporated into RNA, while 5-Fluoro-2'deoxyuridine-5,-
triphosphate (FdUTP) may be incorporated into DNA. This
complicated mechanism of action offers the possibility to
selectively modulate the mechanism of action of 5FU
(Martin, 1987). Both cytostatic drugs and natural compounds
have been used for this purpose. Since the metabolism of
5FU may be different in tumours compared to normal
tissues such as gut and bone marrow, biochemical modula-
tion of 5FU is a reasonable approach to improve the therapy
with 5FU.
It has been reported that mice can be 'rescued' from lethal
toxicity of 5FU by delayed administration of uridine (Martin
et al., 1982; Klubes et al., 1982,1983). Klubes et al. (1982)
used a 5 day subcutaneous infusion of uridine, which was
initiated 24h after a single i.p. bolus injection with 5FU. The
approximate LD10 of 5FU was more than tripled. In a
subsequent paper (Klubes et al., 1983) it could be
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demonstrated that the therapeutic efficacy against murine
B16 melanoma could be enhanced, but that treatment of
L1210 leukaemia was not more effective. Martin et al. (1982)
administered uridine as high dose bolus injections starting
2 h after 5FU. This schedule reduced 5FU induced
leukopenia. In a drug combination of 5FU with N-
(phosphonacetyl)-L-aspartate (PALA) and 6-methylmercapto
purine riboside (MMPR) the maximum tolerated dose could
be enhanced in the presence of uridine, resulting in an
improved antitumour activity against Colon 26. The
mechanism for the selective rescue by uridine is not yet
completely clarified. However, evidence has been presented
that the uridine rescue resulted in a faster clearance of 5FU
incorporated into RNA of both tumour and bone marrow.
In bone marrow the recovery of DNA synthesis is markedly
increased by uridine (Martin et al., 1982). The reduction of
5FU in RNA is probably due to the increase in UTP
(Sawyer et al., 1984). Gastrointestinal toxicity of 5FU might
be related to 5FU incorporation into RNA (Houghton et al.,
1979) rather than to increased FdUMP levels. The selective
effect of uridine on RNA might be related to the selectivity
of uridine 'rescue'. Recently Martin (1987) reported that
cytidine can also rescue mice from 5FU toxicity.
Clinical application of uridine rescue was initiated as I h
infusions (Leyva et al., 1984) in which 2mm peak levels of
uridine were reached. However, uridine was eliminated
rapidly, preventing maintenance of long term exposure of
tissue to high uridine levels. For this reason uridine was
administered as a continuous infusion (Van Groeningen et
al., 1986a), but administration had to be discontinued due to
the occurrence of fever (Van Groeningen et al., 1986a; Peters
et al., 1987a). Fever was also observed after uridine
administration to rabbits (Peters et al., 1987a; Cradock et
al., 1986). The occurrence of fever was not due to the
presence of bacterial pyrogens. In contrast, high dose uridine
caused severe hypothermia in mice and rats (Peters et al.,
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1987b). An intermittent administration schedule of uridine
prevented the appearance of fever (Van Groeningen et al.,
1986a) and it could be demonstrated that with this schedule
5FU-induced leukopenia could be reversed (Van Groeningen
et al., 1986b).
In the studies of Martin et al. (1982) only the effect of
uridine on toxicity of high dose 5FU was studied. However,
in patients the use of these high doses of 5FU is often not
possible. Therefore it was of interest to study the effect of
uridine at nonlethal 5FU doses on leukocytes. We also
monitored thrombocyte and red blood cell counts. Since the
sensitivity of 5FU sensitive tumours should not be reversed
by uridine, the effect of uridine on the sensitivity to 5FU of
the sensitive tumour Colon 38 was studied and compared
with the results on the effect of uridine on the antitumour
activity of 5FU on the relatively resistant tumour Colon 26.
Since oral administration of uridine was found to produce
low plasma uridine levels (Klubes et al., 1986; Van
Groeningen et al., 1987; Au et al., 1987), and cytidine
administration also resulted in relatively low uridine plasma
levels (Peters et al., 1987a,b), it was of interest to study the
effect of low uridine and of cytidine on the sensitivity to
5FU in cell culture.
Materials and methods
Materials
The origins of the cell lines, culture media and foetal bovine
serum have been described previously (Peters et al., 1986).
5FU for injection was obtained from Hoffman-La Roche,
Mijdrecht, The Netherlands; 5FU for biochemical experi-
ments was obtained from Sigma, St. Louis, MO, USA. RNase
was obtained from Boehringer, Mannheim, FRG. Pyrogen-
free uridine intended for injection was prepared as a 20%
solution by the Pharmacy Department as described previously
(Leyva et al., 1984). [6-3H]-SFU, was obtained from the
Radiochemical Centre Amersham, UK and Soluene-350
from United Packard Technologies, Groningen, The
Netherlands. All other chemicals were of analytical grade.
Cell culture
Cells were routinely cultured in 10% undialyzed, heat-
inactivated foetal bovine serum in 20mM HEPES-buffered
Dulbecco's MEM medium in 75cm2 culture flasks at 37°C
under an atmosphere of 5% CO2. Growth inhibition
experiments were performed with 15% dialyzed serum in 6
well cluster plates (10cm2) essentially as described previously
(Peters et al., 1986). 5FU was added to the cultures 24h
after passage of the cells. The extent of growth inhibition
was calculated as described previously (Peters et al., 1986).
Dilute plating assay
WiDr and Intestine 407 cells were seeded in 6 well plates at
a concentration of 150 cells per well in triplicate. For assay
of drug effects 15% dialyzed foetal bovine serum was used.
5FU was added to the wells after 24h, while uridine was
added after 48 h. Colonies were counted when they reached a
size of 50-100 cells. Colonies were stained after removal of
the medium with 0.1% crystal violet in 0.85% saline for
30min. The effect of drugs was evaluated by calculation of
the T/C value (T, number of colonies in treated cultures; C,
number of colonies in control cultures).
5FU incorporation into RNA and binding ofFdUMP to
thymidylate synthase
Measurement of 5FU incorporation into RNA and binding
of FdUMP to thymidylate synthase was performed as
described previously (Peters et al., 1987c) at 14pM 5FU final
concentration after 2 and 4h. Uridine or cytidine were added
2h after addition of 5FU and 5FU incorporation was
measured 2h later.
Antitumour activity and haematological toxicity ofSFU
Two murine colon carcinoma tumour lines were used which
were maintained in 2 month old female mice, Colon 26 in
BALB/c mice, and Colon 38 in C57B1/6 mice. Tumours were
transplanted s.c. in small fragments of 1-5 mm3.
Characteristics and origin of both tumours have been
previously described (Corbett et al., 1975; Van Kranenburg-
Voogd et al., 1978; Peters et al., 1987d) and are summarised
in Table I. Tumours were measured by caliper measurement
every 3-4 days and volumes were calculated by multiplying
length x width x height x 0.5. The NCI protocol of
length x width2 x 0.5 was not used because of the irregular
size of the tumours. Inclusion of height in the calculation
improved the accuracy of measurements. The treatment was
started when tumour volume was 50-150mm3. Mice were
treated by i.p. injection. Time of treatment was standardized
since antitumour activity and toxicity of 5FU show a diurnal
variation (Peters et al., 1987d). SFU was administered
between 15.00 and 16.00h; uridine between 17.00 and 18.00h
and the next day between 11.00 and 12.00h. Antitumour
activity was evaluated by calculation of the T/C (tumour size
of treated mice divided by tumour size of control mice)
essentially as described previously (Peters et al., 1987d). A
restricted randomization was used, leading to groups of 6
mice for each treatment schedule.
Haematological toxicity was evaluated by measurement of
the leukocyte and thrombocyte count, the haematocrit (Ht)
and haemoglobin level. Weekly blood samples were obtained
by retroorbital puncture under slight ether anaesthesia.
Blood samples were obtained between 09.00 and 10.00h and
analyzed immediately. Non-tumour bearing healthy 3-month
old female C57BI/6 mice were used for the study of
haematological toxicity. Tumour bearing mice could not be
used for these studies, because of their restricted life span
due to tumour burden. This would not enable us to follow
blood cell counts for an extended period.
Results
Cell culture
The effect of uridine on the cytotoxicity of 5FU was studied
in the human colon carcinoma cell line WiDr and the human
intestinal epithelial cell line Intestine 407. The growth
inhibitory effects of 5FU were studied previously; the IC50
values were 0.7pM for WiDr and 1.7pM for Intestine 407
(Peters et al., 1986). The effect of uridine was studied at 3
and 10pM 5FU, which inhibited growth partly and
completely, respectively (Figure 1). After 24h, medium
containing 5FU was aspirated and replaced by fresh medium
or medium containing uridine. Fresh medium did not restore
growth of the cells. Growth of WiDr cells pretreated with
3gM 5FU was almost normal after addition of 1 mM uridine,
while growth of Intestine 407 cells was not normal; growth
Table I Characteristics of the colon carcinomas Colon 26 and
Colon 38
Colon 26 Colon 38
Histology Undifferentiated Adenocarcinoma
with local fibro-
sarcoma
Mice BALB/c C57B1/6
tlOO (days)a 12.5 21
TD (days)b 2.8 5.2
Take rate (%) 100 90-95
Median life spanc 19 >40 days
First day of treatmentc 9-10 20
aMedian time at which tumour reaches a size of 100mm3;
bDoubling time of tumour in size range of 50-500mm3; cDays after
transplantation (mean from 10 experiments).URIDINE RESCUE OF 5-FLUOROURACIL 261
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Figure 1 Reversal of the growth inhibitory effects of 5FU by
uridine in WiDr and Intestine 407 cells. Cells were continuously
exposed to either 3 (0 O) or 10 (L- CI)pM 5FU.
Replacement of 5FU containing medium after 24h is indicated
by the broken lines; 0---x, El--- x, 1mM uridine; 0---+,
Fl---+, 0.1 mM uridine; and O---A, El---A, medium.
A A, growth of non-treated control cells. The figure is one
representative experiment out of 3.
rates between 24 and 48h were 1.7 and 1.4, respectively. The
effect of 0.1 mM uridine was intermediate. After pretreatment
of cells with 1OgM 5FU, uridine could not restore growth in
Intestine 407 and only to a small extent in WiDr cells; with
1 mM uridine growth rates between 24 and 48h were 1.2 for
WiDr and 0.9 for Intestine 407 cells. Normal growth rates
between 24 and 48h were 2.0 and 1.8, respectively.
Since it has also been reported that cytidine can rescue
mice from the toxicity of 5FU (Martin, 1987) we also
studied the effect of cytidine on growth inhibition of 5FU.
The effect of cytidine was much less than that of uridine.
Actually, in both cell lines the effect of cytidine was
comparable to the effect of medium refreshment (data not
shown).
Colony formation in the dilute plating assay was also used
for evaluation of the effects of uridine on the cytotoxicity of
5FU. In WiDr cells colonies reached a size of 50-100 cells
after 15 days, while in Intestine 407 cells this size was
reached after 10 days. Plating efficiency in both cell lines was
-80%. Colonies of WiDr cells were more dense than those
of Intestine 407 cells. The effect of 5FU was determined on
the above mentioned days. The kinetics of inhibition of
colony formation were different for the two cell lines; in
WiDr a rather steep curve was observed, in contrast to
Intestine 407 cells (Figure 2). The IC50 values were higher
than observed with the usual growth inhibition experiments
(Peters et al., 1986). Concentrations of 3 and 5gM 5FU were
used for evaluation of the effects of uridine. In WiDr cells
uridine partly reversed the cytotoxic effects of 3 and 5pM
5FU (Figure 3). In Intestine 407 cells colony formation was
almost normal in the presence of uridine.
Effect ofuridine on 5FU metabolism
5FU incorporation into RNA and the binding of 5FU to
thymidylate synthase was studied using a recently described
method (Peters et al., 1987c); measurements were performed
after 2 and 4h (Table II). 5FU incorporation into RNA was
linear during this time period in both cell lines; binding of
FdUMP to thymidylate synthase already reached a plateau
after 2h. Addition of uridine to the incubation mixture after
2h inhibited the further 5FU incorporation into RNA in
WiDr cells. In Intestine 407 cells 5FU incorporation
continued but to a lower extent than in cells to which
uridine was not added. In Intestine 407 cells the effect of
cytidine was comparable to that of uridine, but in WiDr
cytidine did not inhibit 5FU incorporation. Neither uridine
nor cytidine affected FdUMP binding to thymidylate
synthase (data not shown).
Effect of5FU and uridine on tumour growth
The antitumour activity of 5FU against Colon 26 was
studied at 100, 250 and 300mgkg1 (Table III; Figure 4). At
a dose of 100mgkg-1 a slight antitumour activity was
observed (Figure 4a; Table III). Although the first treatment
with this dose of 5FU usually caused a tumour growth delay
as observed in Figure 4a, this effect was not longlasting and
the tumours soon reached sizes comparable to non-treated
groups, leading to death. The data in Table III demonstrate
that the life-span of mice treated with 5FU at 100mgkg-1
was only increased by a few days. The effect of the high
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Figure 2 Effect of 5FU on colony formation in the dilute
plating assay. Values represent relative colony formation
(x 100%) and are means+ s.e. from 3 experiments. IC50 values
were calculated from the individual curves and are 3.6+0.7 for
Intestine 407 and 1.7+0.4 for WiDr (means+s.c.). *--
Intestine 407, 0 0 WiDr.
Figure 3 Effect of uridine on inhibition of colony formation by
5FU. Cells were exposed to 5FU for 24h and medium was
replaced by uridine-containing medium. Bars represent
means+s.e. of 3 separate experiments.
Table II Effect of uridine on the incorporation of
5FU into RNA
WiDr Intestine 407
Control 225+11 200+9
0.mM uridine 120+21 152+13
1.0mMuridine 101+16 148+24
1.0mM cytidine 192+4 150+20
Values are means+s.e. of 3 separate experiments
and represent relative incorporation of 5FU into RNA
at 4h after addition of 5FU. Incorporation of 5FU at
2h was set at 100%, at this time point uridine and
cytidine were added to the incubation mixture.
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Table III Summary of antitumour activity against Colon 26
Dose Days of Maximal Median Weight
Exp. Drug (mgkg-1) treatment T/C% (day)a life spanb lossc
#1 5FU 100 0, 7 17.1 (9) 13 (8) 1.8
SFU 250 0, 7 9.2 (7) 8 4.3
#2 5FU 300 0, 7 10.6 (7) 7 (8) 9.8
5FU-UR 300-3500 0, 7 14.9 (7) 14 7.1
#3 5FU 250 0, 7 11.0 (7) 11 (8) 7.1
5FU-UR 250-3500 0, 7, 14 11.8 (4) 14 6.0
#4 5FU 100 0, 7, 14 59.5 (4) 22 (16) 5.5
#5 5FU 100 0, 7, 14 48.1 (6) 21 (15) 4.0
#6 SFU 100 0, 7 56.0 (4) 15 (11) 4.2
#7 5FU-UR 250-3500 0, 7, 14 31.9 (16) 21 (13) 5.3
aThe day at which difference between T and C was maximal. All values were
significantly different (P<0.01) from controls; bDays after first treatment (within
parentheses the median life-span of the non-treated animals of these experiments); cMean
% weight loss, one day after treatment. UR=uridine; uridine was injected at 2 and 20h
after 5FU.
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Figure 4 Antitumour activity of SFU against Colon 26 and the
effect of uridine (UR). Uridine (3500mgkg-1) was administered
at 2 and 20h after 5FU. Arrows indicate the days of treatment.
Values are means+s.e. of 8-12 tumours. Mice died either from
toxicity of the tumour (controls and mice treated with 5FU at
100mgkg-1) or from toxicity of treatment (5FU at 250 and
300mgkg-1). Values are of at least 4 mice (8 tumours) out of
the usual number 6 at the beginning of the study. Values of a
lower number of mice were not plotted. Arrows indicate the day
of 5FU administration. Shown are (a) experiment # 1 (5FU
doses 100 * * and 250mgkg-1 * *) and (b) #2
(5FU dose was 300mgkg-' followed by uridine) from Table III,
* * 5FU and * 5FU--UR--UR. 0 O is
control.
doses of 5FU was studied to assess whether uridine could
affect the antitumour activity. In the absence of uridine,
5FU was too toxic for the mice. The observed tumour
growth delay at these high doses could be attributed to the
systemic toxicity of 5FU, which also led to severe weight loss
and decrease in median life span (summarised in Table III).
Delayed administration of uridine prevented mice from
lethal 5FU toxicity, leading to an increased median life span.
The data in Figure 4a demonstrate that the tumour growth
delay after 5FU-uridine treatment was longlasting; the
tumours did not reach sizes comparable with non-treated
tumours. The relative increase in median life span was longer
than that observed with 5FU at lOOmgkg -.
The intention of delayed uridine administration (Martin et
al., 1982; Klubes et al., 1982,1983) is to selectively decrease
systemic toxicity of 5FU. This will allow the use of higher
doses of 5FU resulting in superior antitumour activity
against 5FU-resistant tumours. In order to determine
whether the combination is really selective we also
determined whether the antitumour activity of a 5FU-
sensitive tumour was affected by delayed administration of
uridine at a moderately toxic dose of 5FU. Colon 38 was
sensitive to 5FU (Figure 5). In contrast to Colon 26, at the
low dose of 100mgkg-1 several Colon 38 tumours
completely regresssed (Table IV; Figure 5) while for the
other tumours a significant growth delay was observed.
Delayed administration of uridine did not significantly affect
the antitumour activity of 5FU at this relatively low dose.
The number of regressions was comparable, while the
difference between 5FU-treated groups and 5FU-uridine was
not significant.
Haematological toxicity
In C57BI/6 mice we studied whether uridine could also
prevent bone marrow suppression caused by a therapeutic
dose of 5FU, in contrast to the toxic doses used by others
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Figure 5 Antitumour activity of SFU against Colon 38. SFU
was administered at 100mgkg-' and uridine at 3500mgkg-1.
Values are means+s.e. of 8-12 tumours. The data presented are
from one representative experiment comparing 5FU and SFU
plus uridine. The complete response rate observed with SFU
alone was 22% (10 out of 46 tumours; combined data of 4
separate experiments); with 5FU plus uridine a complete
response rate of 21% was observed (9 out of 43 tumours;
combined data of 4 separate experiments). When tumour size of
the mice reached a volume of 1500-2500 mm3 the mice were
sacrificed. Experiment 5 of Table IV is shown. 0 O control,
*-* 100 mg SFUkg-1, * 0 SFU - uridine.
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Table IV Summary ofantitumour activity against Colon 38
Days of Maximal Weight
Exp. Drug Dose treatment TIC (day)a Iossc
#1 5FU 100 0, 7, 14, 21 2.9 (24) 4.8
#2 5FU 100 0, 7, 14, 21 0.1 (31) 2.4
5FU-UR 100-3500 0, 7, 14, 21 0.5 (31) 3.0
#3 5FU-UR 100-3500 0, 7, 14, 21 9.7 (25) 3.2
#4 5FU-UR 100-3500 0, 7, 14, 21 6.0 (26) 3.6
#5 5FU 100 0, 7, 14, 21 6.9 (24) 3.0
5FU-UR 100-3500 0, 7, 14, 21 17.4 (24) 1.2
#6 5FU 100 0, 7, 14, 21 15.4 (25) 4.3
For explanation of legend, see Table III. Life-span of all mice
exceeded 40 days. Mice were sacrificed when tumour volume was
>2000mm3. All values were significantly different (P<0.01) from
controls.
(Martin et al., 1982; Klubes et al., 1982, 1983). The use of
peripheral blood cell counts for interpretation of bone
marrow toxicity has several limitations (Schofield, 1986).
However, in patients this is the usual method for assessment of
myeloid toxicity, since serial bone marrow punctures are not
feasible. Serial bone marrow punctures in one mouse are also
not feasible, while serial blood collection over an extended
period did not cause problems. For this reason, and to be
able to compare the results with usual procedures in the
clinic, we followed peripheral blood cell counts. C57Bl/6
mice were treated with 100mg 5FUkg-1 and this dose of
5FU was followed by uridine, similar to the dose used for
assessment of antitumour activity (Figure 5). 5FU alone
caused a moderate to severe leukopenia with a nadir at 19
days after the first treatment (Figure 6a). 5FU followed by
delayed uridine also caused leukopenia but the mice
recovered earlier; the nadir was at 12 days. In both groups
the leukopenia was followed by a rebound in leucocyte
count.
5FU alone caused thrombocytopenia to only a very
limited extent. However, after discontinuation of treatment a
rebound in thrombocyte count was observed (Figure 6b).
5FU in combination with uridine did not affect the
thrombocyte count. 5FU decreased the Ht value significantly
(Figure 6c), the nadir being observed after 19 days, similar
to the nadir of the leukopenia. Delayed uridine adminis-
tration prevented the decrease in Ht. A similar effect of 5FU
was also observed on haemoglobin. Pretreatment value was
8.6+ 1.0mmolI -1 (mean+s.d. of 19 mice). 5FU treatment
decreased haemoglobin to 3.1 +0.8mmolI1 at 19 days, while
uridine prevented this decrease (6.2+0.7mmolI1; means
+s.d. of 6 mice).
Discussion
In previous studies (Martin et al., 1982; Klubes et al.,
1982,1983) it was demonstrated that delayed uridine
administration could prevent toxicity induced by high doses
of 5FU. Martin et al. (1982) used 5FU in combination with
PALA and MMPR. In this paper we demonstrate that the
therapeutic efficacy of single agent 5FU against the relatively
resistant tumour Colon 26 could be enhanced by
combination with uridine. The sensitivity of the 5FU-
sensitive Colon 38 was hardly affected, while uridine reduced
haematological toxicity of the relatively low but therapeutic
dose of 5FU. In vitro it could be demonstrated that reversal
of 5FU toxicity was related to both the dose of 5FU, and of
uridine.
In cell culture the reversal of the cytotoxic effects by
uridine is dependent on the mechanism of action of 5FU in
a particular cell line. Previously we demonstrated that the
mechanisms of action of 5FU in WiDr and Intestine 407
cells are different (Peters et al., 1986, 1987c; in WiDr cells
5FU incorporation into RNA might contribute more to the
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Figure 6 Haematological toxicity of 5FU (100mgkg-1;
--- U) and of 5FU (100mgkg-1) plus uridine ( *).
The value at day 0 is of 18 mice, other values are of 5-7 mice and
represent means+s.e. Closed asterisk, P<0.01; open asterisk,
0.02<P<0.05; differences are those between treated and control
groups. Arrows indicate the days of treatment. (a) leukocyte
count, difference at day 19 is significant between the 5FU and
5FU plus uridine groups at the level, P<0.001; (b) thrombocyte
count, difference between 5FU and 5FU plus uridine groups is
significant at day 5 at the level 0.02<P<0.05; (c) Ht value,
difference between 5FU and 5FU plus uridine groups is
significant at day 19 at the level P<0.01.
effects of growth inhibition than in Intestine 407 cells. At
1 mM uridine the reversal of growth inhibition in WiDr
appeared to be more pronounced. The prevention of
continuation of 5FU incorporation into RNA in WiDr cells
is in accordance with the above mentioned mechanism of
action of 5FU.
The in vitro data also indicate that a rather low
concentration of uridine (0.1 mM) is sufficient for at least
partial reversal of growth inhibition. Even such a partial
reversal might be enough to prevent or reduce toxicity.
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Martin et al. (1982) postulated that plasma uridine
concentrations of 1 mM might be sufficient to induce rescue.
However, in tissues uridine concentrations are not elevated
to the same extent as in plasma (Peters et al., 1987b), which
might be related to the mechanism of uptake of uridine in
tissues (Darnowski & Handschumacher, 1986). In mice we
demonstrated that both in Colon 38 and normal tissues
uridine nucleotides increased after uridine administration,
but in the tumour the relative increase was lower (Peters et
al., 1987b). It has been demonstrated that at physiological
uridine levels, uridine conversion to nucleotides proceeded at
a rather high rate in blood cells compared to other issues
(Moyer et al., 1981). Furthermore, blood cells and probably
also bone marrow cells are in direct contact with high
uridine concentrations (in mice from 10-20mM; in patients
from 300-1000UM using intermittent i.v. administration; see
Van Groeningen et al., 1986a; Peters et al., 1987a,b). Since
uridine kinase activity is relatively high in these cells (Sawyer
et al., 1984; Peters et al., 1983) and the Km of uridine for
uridine kinase is 0.1 mM (Cihak & Rada, 1976), uridine
will be converted to nucleotides at a high rate. This might
lead to a higher ratio of total uridine nucleotides/total
fluorouridine nucleotides in bone marrow cells and
peripheral blood cells than in solid tissues. So the selectivity
of uridine 'rescue' might both be related to a different
mechanism of action of 5FU in normal tissues compared to
tumour tissue, but also to a more selective enhancement of
uridine metabolism in myeloid cells. With oral uridine rather
low plasma uridine concentrations (50-100/M) were
achieved in mice (Klubes et al., 1986), rats (Au et al., 1987)
and man (Van Groeningen et al., 1987). It could be
demonstrated that such low uridine concentrations are
sufficient to expand the uridine nucleotide pool in L1210
cells (Karle et al., 1984). Our in vitro results also
demonstrated that rather low uridine concentrations are
sufficient to (partially) reverse 5FU toxicity and inhibit 5FU
incorporation into RNA. As yet it has to be demonstrated
whether the low uridine concentrations reached after oral
uridine might also be sufficient to 'rescue' patients from 5FU
toxicity.
The antitumour activity of 5FU against Colon 26 and
Colon 38 is comparable to that described previously (Corbett
et al., 1975; Van Kranenburg-Voogd et al., 1978) although
the tumours are from a later passage and different mouse
strains have been used. Martin et al. (1982) also studied
Colon 26, but lower doses of 5FU were used (125mgkg-1)
in combination with uridine, or 5FU was used in
combination with PALA and MMPR. We demonstrated that
at a high dose of 5FU combined with uridine comparable
results to those obtained when 5FU is incorporated in a
combination regimen (Martin et al., 1982) could be achieved.
The time course and extent of leukopenia induced by 5FU
alone are comparable to those described previously (Yeager
et al., 1983). However, the toxic effect of 5FU on the Ht was
not described (Yeager et al., 1983), nor the protecting effect
of uridine on the Ht and haemoglobin (Martin et al., 1982;
Klubes et al., 1982). The peripheral blood cell counts may
not reflect cytotoxicity to bone marrow stem cells (Schofield,
1986) nor reflect a protective effect of uridine. It cannot be
excluded that high concentrations of 5FU affect resting cells,
but the exposure of peripheral blood to high 5FU levels is
very short due to rapid elimination of 5FU from the blood.
Therefore it is unlikely that the decrease in red blood cells
and leukocytes is due to toxicity of the peripheral cells, but
5FU apparently inhibited the renewal of red blood cells and
leukocytes, which could be prevented by uridine. 5FU did
not cause thrombocytopenia, but the self renewal of
thrombocytes might be enhanced during treatment. This may
be reflected by the rebound in thrombocyte counts in the
5FU treated group. The absence of a rebound effect in the
combination of 5FU plus uridine suggested that uridine also
prevented toxic effects of 5FU on thrombocytes.
The use of uridine for control of 5FU toxicity in the
clinical situation is currently under investigation. Using an
intermittent administration of uridine, leukopenia induced by
5FU (Van Groeningen et al., 1986b) could be reversed but
thrombocytopenia could not. However, from these
preliminary results it cannot be concluded that the clinical
application of 5FU in combination with uridine will be
successful. In addition, in a randomized study it has to be
proven whether in patients the response rate of 5FU will not
decrease when 5FU is combined with uridine. From our
murine data with Colon 38 it appears that sensitivity of 5FU
at a low therapeutic dose is not affected. From our in vitro
data it may be concluded that low levels of uridine (as
observed with oral uridine) might be sufficient to affect the
toxicity of 5FU by interference with the incorporation of
5FU into RNA. So the use of higher doses of 5FU in
combination with either intermittent i.v. or oral uridine
might have improved therapeutic efficacy.
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